Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study - 14/10/22
Doi : 10.1016/j.jaad.2022.06.031
Nicole Trepanowski, BS a, b, Michael S. Chang, MD b, c, Guohai Zhou, PhD b, Maham Ahmad, BA d, Elizabeth G. Berry, MD e, Katherine Bui, DO f, William H. Butler, BA b, c, Emily Y. Chu, MD, PhD g, Clara Curiel-Lewandrowski, MD h, i, Laura E. Dellalana, MD j, Darrel L. Ellis, MD j, k, S. Caleb Freeman, MD e, Pavane L. Gorrepati, BA l, Douglas Grossman, MD, PhD m, Samvel Gyurdzhyan, BA n, Peter A. Kanetsky, MPH, PhD o, Amber Loren Ong King, MD d, Avani M. Kolla, BPhil p, Christine G. Lian, MD q, Jennifer Y. Lin, MD b, Vincent Liu, MD r, Annie Lowenthal, AS m, Kelly N. McCoy, MD s, Ananya Munjal, MS l, Caitlyn N. Myrdal, MD h, Sara Perkins, MD d, Jennifer G. Powers, MD t, Corinne Rauck, MD g, Tristan C. Smart, BA, MPA m, Jennifer A. Stein, MD, PhD p, Suraj Venna, MD u, v, Madalyn E. Walsh, MD w, Jennifer Y. Wang, MD x, Sancy A. Leachman, MD, PhD e, y, Susan M. Swetter, MD x, z, Rebecca I. Hartman, MD, MPH b, c, aa, ⁎ 
a Boston University School of Medicine, Boston, Massachusetts
b Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
c Harvard Medical School, Boston, Massachusetts
d Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
e Department of Dermatology, Oregon Health & Science University, Portland, Oregon
f Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
g Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
h Division of Dermatology, The University of Arizona College of Medicine, Tucson, Arizona
i The University of Arizona Cancer Center, Tucson, Arizona
j Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
k Department of Dermatology, Nashville VA Medical Centers, Nashville, Tennessee
l University of Iowa Carver College of Medicine, Iowa City, Iowa
m Department of Dermatology and Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah
n Stanford University School of Medicine, Stanford, California
o Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
p The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York
q Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
r Departments of Dermatology and Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa
s University of Virginia, Charlottesville, Virginia
t Department of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, Iowa
u University of Virginia School of Medicine, Charlottesville, Virginia
v Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, Virginia
w Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa
x Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Palo Alto, California
y Knight Cancer Institute at Oregon Health & Science University, Portland, Oregon
z Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
aa Department of Dermatology, VA Integrated Service Network (VISN-1), Jamaica Plain, Massachusetts
∗Reprint requests: Rebecca I. Hartman, MD, MPH, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115Department of DermatologyBrigham and Women’s Hospital221 Longwood AveBostonMA02115
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| Drs Trepanowski and Chang are co-first authors. |
|
| Funding sources: This study was funded by the Melanoma Research Foundation. Dr Hartman is supported by a VISN-1 Career Development Award. This material is the result of work supported with resources and the use of facilities at the Nashville VA Medical Centers, Nashville, Tennessee (Ellis), VA Palo Alto Health Care System, Palo Alto, California (Swetter), and the VA Boston Health Care System, Jamaica Plain, Massachusetts (Hartman). |
|
| IRB approval status: Approved by the University of Arizona College of Medicine and Cancer Center (Protocol #2102533607), Brigham and Women’s Hospital/Dana Farber Cancer Institute (Protocol #2020P003204), Inova Schar Cancer Institute (Protocol #U21-03-4415), University of Iowa Hospitals & Clinics (Protocol #202101646), H. Lee Moffitt Cancer Center and Research Institute (Protocol #00000971), NYU Grossman School of Medicine (Protocol #i21-00123), Oregon Health & Science University (Protocol #STUDY00022683), the University of Pennsylvania (Protocol #848431), Stanford University Medical Center and Cancer Institute (Protocol #IRB-60789), University of Utah Health Sciences Center (Protocol #140300), Vanderbilt University Medical Center IRB (Protocol #210417), and Yale University School of Medicine (Protocol #2000029997). |
|
| Key words: coronavirus; COVID-19; delay; melanoma; nodular; pandemic; presentation; prognosis; skin cancer; stage; subtype; thickness; treatment; ulceration. |
© 2022
Publié par Elsevier Masson SAS.
Vol 87 - N° 5
P. 1217-1219 - novembre 2022 Retour au numéro
Article précédent
- Assessing the role of stressful life events in the induction and recurrence of alopecia areata: A case-control study
- Panagiotis Ferentinos, Eugenia Kalogeropoulou, Georgia Pappa, Anastasia Antoniou, Evangelia Bozi, Miltiades Kyprianou, Dimitrios Rigopoulos, Alexandros C. Katoulis
- A health equity framework to address racial and ethnic disparities in melanoma
- Avani M. Kolla, Azizi Seixas, Prince Adotama, Victoria Foster, Simona Kwon, Vivienne Li, Ann Y. Lee, Jennifer A. Stein, David Polsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.